Skip to main content
Premium Trial:

Request an Annual Quote

Duncan Whitney, Samuel Broder, Daniel Von Hoff, David Owen, Greg Lucier, Dennis Mickey Flynn, Fritz Bittenbender, Peter Schultz, Ted Love, George Rathmann, and more



Duncan Whitney has become vice president of research and development at US Genomics, the company said last week. He joins US Genomics from Exact Sciences, where he was vice president of technology. Prior to that, he held senior management positions at Molecular Geodesics, PerSeptive Biosystems, and Polaroid. Whitney has a PhD in polymer sciences from the Massachusetts Institute of Technology and a BS in chemistry from Colby College.

Samuel Broder has joined the board of directors of Protein Design Labs, the Fremont, Calif.-based company said yesterday. He is the chief medical officer of Celera Genomics and Celera Diagnostics. Prior to that, he was senior vice president for research and development at Ivax, and before that, director of the National Cancer Institute. Broder has a medical degree and a bachelor's degree from the University of Michigan.

Daniel Von Hoff has joined the scientific advisory board of Spectrum Pharmaceuticals, the Irvine, Calif.-based company said on Monday. He is a senior investigator and head of translational research at the Translational Genomics Research Institute in Arizona. He is also the chief scientific officer for US Oncology.

David Owen has been appointed as a non-executive director of Oxford Gene Technology, the company said this week. He is the non-executive chairman of Abcellute and of the Cardiff Partnership Fund as well as co-chairman of EMBL Enterprise Management. Owen holds a PhD in pharmacology.

Greg Lucier has become a member of the board of trustees of the Burnham Institute, the La Jolla, Calif.-based institute said last week. He is president and chief executive officer of Invitrogen.

Dennis "Mickey" Flynn will become president of the Pennsylvania Bio Board, effective Nov.1, the bioscience industry organization said last week. He will succeed Fritz Bittenbender, who will become senior director of corporate affairs at Cephalon. Flynn joins Pennsylvania Bio from Puresyn, where he was president.

Peter Schultz has joined the board of directors of Nanosphere, the Northbrook, Ill.-based company said last week. He is professor of chemistry at the Scripps Research Institute as well as director of the Genomics Institute of the Novartis Research Foundation, also based in La Jolla. In addition, Schultz is a founder of Affymax Research Institute, Symyx Technologies, Ambrx, Syrrx, Kalypsys, Phenomix, and Ilypsa. He holds a doctoral and a bachelor's degree from the California Institute of Technology.

Ted Love has been appointed as chairman of the board of directors of Nuvelo, the company said last week. He is the president and CEO of Nuvelo. Love replaces George Rathmann, who will remain on the board as chairman emeritus.

In addition, Barry Zubrow, currently vice chairman of Nuvelo's board, will also become the lead independent director.

Vicki Chandler and Titia de Lange are among the 13 winners of the 2005 NIH Director's Pioneer Award announced by the National Institutes of Health last week. The award, which comes with $2.5 million in direct costs over five years, supports "exceptionally creative scientists who take innovative approaches to major challenges in biomedical research," according to NIH. Chandler is a professor of plant sciences and molecular and cellular biology at the University of Arizona in Tucson, where she studies the control of gene expression. De Lange is a professor and head of the laboratory of cell biology and genetics at Rockefeller University, where she studies telomeres.


New Releases

GE Healthcare is currently offering 25 percent off on the purchase of a complete Ultrospec pro package spectrophotometer.

Affymetrix last week launched its GeneChip Human Exon 1.0 ST array, which offers whole-genome, exon-level expression profiling on a single array, the company said in a statement. The array is designed to interrogate approximately one million exons, the company added.

Affymetrix' Exon Array System, also launched last week, features the array, optimized reagents, Affy's Exon Array Computational Tool for detection and signal estimation and access to the NetAffx Analysis Center and the Integrated Genome Browser for analysis and array design information and annotation. The Array Station was co-developed with Caliper Life Sciences and features an upgraded Caliper SciClone liquid-handling workstation and an on-board Twister II plate handler, GeneChip microarrays, optimized assays and reagents, as well as open software architecture, Affy said.

The GeneChip Mapping 500K Array Set is the third product Affy launched last week. The set is made up of two arrays, each capable of genotyping on average 250,000 SNPs for whole-genome associational studies, the company said. It is optimized to run with several of the company's assays, including the ParAllele Assay, and works on Affy's standard platform of the GC Scanner 3000 7G, Hybridization Oven 640, Fluidics Station 450, and GC Genotyping Analysis Software and Operating Software.

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.